Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INTACT-WT1: Donor-derived WT1 and Pathogen Specific T Cells for AML Post-Transplant
NCT02895412Phase 1Unknown
- Sponsor
- University of Sydney
- Start
- Aug 2016
- Primary completion
- Dec 2020
- Modality
- TCR-Engineered T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of WT1-CTL in acute myeloid leukemia (AML), sponsored by University of Sydney. Primary endpoint: Number of participants with treatment-related adverse events at 2 Years. Status: unknown.
02
Drugs
WT1-CTL
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT02895412.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02895412.